Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RD01 in healthy Chinese subjects
NCT03657238Phase 1Completed
- Sponsor
- Shenzhen Sciprogen Bio-Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anemia comparing RD01 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events up to 35 days. Started Apr 2018; status: completed.
02
Drugs
pegerthropoietin
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03657238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657238.